Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 2]
A Phase 2 clinical trial evaluating FG-3246 in metastatic castration-resistant prostate cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan
An observational registry update (PULSE Registry) for patients receiving lutetium-177 vipivotide tetraxetan in metastatic prostate cancer; r…
-
CLINICAL_TRIALS trial_result · 2026-03-19Clinical Trial Update: A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) [Phase 1]
This trial update reports the completion of a Phase 1 study of Opevesostat (MK-5684) in Chinese participants with metastatic castration-resi…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) [Phase 2]
AstraZeneca's Dato-DXd is being studied as a single agent and in combination with other anti-cancer drugs in an ongoing Phase 2 trial for ad…
-
EMA approval · 2026-03-17EMA Authorised: Akeega (abiraterone acetate;niraparib (tosilate monohydrate)) — Janssen-Cilag International N.V.
EMA authorised Akeega, a fixed-dose combination of abiraterone acetate and niraparib (tosilate monohydrate) for castration-resistant prostat…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]
A Phase I study is evaluating [225Ac]-AZD2284 in metastatic castration-resistant prostate cancer, and the trial is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC [Phase 2]
Phase 2a trial evaluating high-dose testosterone prior to radioligand therapy in metastatic castration-resistant prostate cancer; currently …
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer [Phase 1]
Phase 1 PET imaging study evaluating 89Zr-DFO-YS5 in men with prostate cancer, including metastatic castration-resistant disease; the trial …
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: 64Cu-GRIP B in Patients With Advanced Malignancies [Phase 1, Phase 2]
Clinical trial update for a Phase 1/Phase 2 study of 64Cu-GRIP B in advanced malignancies, including prostate and renal cancers, which is cu…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer [Phase 2]
A Phase 2 trial evaluating a combination of apalutamide, abiraterone acetate, and prednisone in metastatic castration-resistant prostate can…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the safety of TD001 in patients with PSMA-expressing metastatic castration-resistant prostate cance…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial [Phase 2]
A Phase 2 clinical trial (RE-LuPSMA, NCT06288113) is evaluating re-treatment with Lutetium-177 PSMA-617 for metastatic castration-resistant …
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors [Phase 1]
A Phase 1 study evaluating Zanzalintinib in combination with immuno-oncology agents in patients with various solid tumors; recruitment is on…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: PROCARE - PROstate Cancer Real World Evidence Registry
PROCARE is a prostate cancer real-world evidence registry that is currently recruiting participants, collecting data across multiple disease…
-
CLINICAL_TRIALS trial_result · 2026-03-11Clinical Trial Update: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response [Phase 2]
Phase 2 trial update suggests supraphysiologic testosterone priming may extend the response to darolutamide in metastatic castration-resista…
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 study evaluating tazemetostat in combination with enzalutamide or abiraterone/prednisone in advanced/metastatic prostate cancer …
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) [Phase 2]
A Phase 2 randomized trial is evaluating a flexible dosing schedule of 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer, w…
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial update on palbociclib for metastatic castration-resistant prostate cancer; the study is currently active and not recr…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) [Phase 1]
Phase 1 clinical trial update of Opevesostat (MK-568) in Japanese participants with metastatic castration-resistant prostate cancer; the stu…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function [Phase 2]
Phase 2 clinical trial evaluating Lutetium-177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer patients with varyin…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) [Phase 3]
Phase 3 study comparing Xaluritamig with cabazitaxel or a second androgen receptor-directed therapy in progressive metastatic castration-res…
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial is testing combinations of abiraterone acetate with prednisone and apalutamide, with or without ipilimumab or cabaz…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer [Phase 1]
A Phase 1 trial evaluating sipuleucel-T–based autologous cellular immunotherapy for advanced prostate cancer is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway [Phase 1]
Phase 1 trial of DCC-3084 for MAPK-pathway driven advanced cancers has been terminated. The update notes the study status without presenting…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC [Phase 2]
A Phase 2 trial evaluating SHR-1701 in combination with stereotactic body radiotherapy for metastatic castration-resistant prostate cancer i…